Entera Bio

ENTXPhase 2

Jerusalem, IsraelFounded 2010enterabio.com

Entera Bio is pioneering the oral delivery of biologics, a significant challenge in pharmaceutical development. Its core platform technology is designed to facilitate the gastrointestinal absorption of large molecules, potentially transforming treatment paradigms for chronic conditions requiring frequent injections. The company's most advanced candidates, EB613 for osteoporosis and EB612 for hypoparathyroidism, have demonstrated proof-of-concept in clinical trials. Entera's strategy focuses on developing oral formulations of established peptide hormones to create more patient-friendly therapies.

Market Cap

$50.9M

Founded

2010

Employees

11-50

Focus

Biotech

ENTX · Stock Price

USD 1.111.65 (-59.78%)

Historical price data

AI Company Overview

Technology Platform

Proprietary oral drug delivery platform designed to enable gastrointestinal absorption of large molecule therapeutics, such as peptides and proteins, using generally recognized as safe (GRAS) absorption enhancers.

Pipeline Snapshot

6 drugs in pipeline

Drug	Indication	Stage
EnteraBio's Oral Parathyroid Hormone (1-34)	Hypoparathyroidism	Phase 2
EBP05 + Placebo of EBP05	Osteoporosis	Phase 2
EB612 (EBP05) + NATPARA/NATPAR	Hypoparathyroidism	Phase 2
EBP05 + Forteo 0.02 mg + EBP11 + EBP22 + EBP11-F2 + EBP11-F4 + EBP11-F1 + EBP11-...	Hypoparathyroidism	Phase 1
Teriparatide + Oral PTH (1-34)	Drug Safety and Bioavailability	Phase 1

Funding History

Total raised: $37M

PIPE$10MUndisclosedNov 15, 2021

IPO$15MUndisclosedJun 15, 2018

Series A$12MPontifaxMar 15, 2016

Opportunities

A successful Phase 3 readout for EB613 would validate the oral delivery platform, creating significant value and enabling partnerships for commercialization.

The platform technology also presents opportunities to develop oral formulations of other peptide drugs in endocrinology and beyond through licensing deals.

Risk Factors

The company faces a binary clinical risk with its Phase 3 trial for EB613.

It has a limited cash runway and will likely need to raise additional capital, risking shareholder dilution.

Regulatory hurdles and future competition pose additional challenges.

Competitive Landscape

Entera's main competitors are injectable anabolics in osteoporosis (e.g., Forteo, Tymlos) and standard care in hypoparathyroidism. Its key differentiation is the oral route of administration. It also competes with other oral biologic delivery platforms, but its focus on specific peptides with GRAS excipients is a distinct approach.